TrumpRx Platform Sees Steady Growth in Discounted Prescription Offerings, Delivering Major Savings as Key Pillar of MAHA Initiative

WASHINGTON – The Trump administration’s TrumpRx.gov website, launched as a centerpiece of the Make America Healthy Again (MAHA) agenda, continues to expand rapidly, adding new medications and pharmaceutical partners while providing cash-pay patients with dramatic price reductions aligned to the lowest rates paid in other developed nations.

President Donald Trump unveiled the platform on February 5, 2026, promising to end the decades-long practice of American patients subsidizing lower drug prices overseas. Through Most-Favored-Nation (MFN) pricing agreements with manufacturers, TrumpRx directs users to manufacturer websites or printable coupons where they can purchase brand-name drugs at prices matching the lowest paid internationally — often 50 to 90 percent below U.S. list prices.

The site launched with 43 high-cost medications from five initial partner companies: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. It focused on widely used treatments for conditions including obesity, diabetes, asthma, infertility, osteoporosis, and multiple sclerosis.

By March 27, 2026, the catalog has grown to 54 medications involving six participating manufacturers. Recent additions include drugs from Amgen and GSK, with more than 16 pharmaceutical companies now having entered MFN pricing agreements with the administration for future rollouts.

Specific examples of the savings now available include:

• Amgen’s Amjevita (adalimumab-atto), used for rheumatoid arthritis, psoriasis, and ulcerative colitis: $299 — an 80 percent discount from the U.S. list price of $1,484.16.
• GSK’s Incruse Ellipta (umeclidinium), for chronic obstructive pulmonary disease (COPD): $159.20 — a 55 percent reduction from $354.10.
• GSK’s Arnuity Ellipta (fluticasone furoate): Starting at $102.98 (51 percent off).
• GSK’s Anoro Ellipta (umeclidinium/vilanterol): $247.94 (49 percent off).
• Amgen’s Aimovig (erenumab-aooe), a migraine treatment: $299 (approximately 62 percent off).
• Amgen’s Repatha (evolocumab), for high cholesterol: $239 (approximately 62 percent off).

Additional offerings now include GSK’s Relenza for influenza, certain fertility treatments, and weight-loss medications, all available at cash-pay rates without requiring insurance.

The White House highlighted the expansion in a February 5, 2026, statement: “President Trump is delivering on promises to ensure American patients no longer pay high prices to subsidize low prices in the rest of the world — something the political establishment did not believe was possible.”

The platform does not sell drugs directly; instead, it serves as a centralized hub providing price comparisons, coupons, and direct links to manufacturer purchasing channels. Officials say this model increases transparency and puts patients — particularly the uninsured or underinsured — in control of their medication costs.

Health and Human Services Secretary Robert F. Kennedy Jr. has tied the program directly to the MAHA initiative, calling it a practical step toward reducing chronic disease and reining in pharmaceutical pricing practices that have burdened American families.

Administration officials expect further substantial discounts and additional high-cost medications to be added on a rolling basis in the coming months. Congressional action on elements of Trump’s broader Great Healthcare Plan is anticipated to accelerate the program’s reach, potentially lowering insurance premiums and increasing overall pricing transparency across the market.

The steady growth of TrumpRx — both in drug offerings and participating companies — is being viewed inside the administration as early proof that MAHA’s market-driven approach to healthcare reform is working, countering skeptics who dismissed the effort as unfeasible. The White House continues to invite additional manufacturers to join the MFN agreements as the platform matures.